What Imai Found, and What They're Still Calling Experimental

What Imai Found, and What They're Still Calling Experimental

In a Washington University lab in St. Louis, a Japanese researcher from Tokyo University gave aging mice back the molecule their cells were running out of. Their bodies ran backwards. Tokyo, Zurich, and Tel Aviv built it into their standard of care. American medicine is still waiting for permission.

St. Louis, 2013. Twenty-Two-Month-Old Mice. Twelve Months. Every System Responded.

There's a reason most American doctors will still tell you NAD+ is "experimental."

Shin-ichiro Imai was doing something nobody had bothered to take seriously. It was simple. He was giving aging mice the precursor molecule their cells were running out of, and watching what their bodies did with it.

The mice were twenty-two months old. In human terms, the equivalent of seventy-year-old men. He gave them NMN orally, for weeks, in their drinking water.

1. Then he ran them on a treadmill.
2. They ran like mice half their age.
3. Their endurance, their grip strength, their mitochondrial output, their insulin sensitivity, their gene-expression patterns. Every parameter the lab measured improved.

The clock didn't just stop. Pieces of it ran backwards.

He was the first person to demonstrate, in a long-term controlled study, that the aging clock could run backwards in a live mammal, by putting one specific molecule back.

That was more than a decade ago. The American medical system is still calling it experimental.

What NAD+ Actually Is, and Where You Are on the Curve

I want to slow down on this, because most people miss it.

NAD+ is not a wellness ingredient. It is not a supplement category. It is the molecule every cell in your body uses to generate energy.

Every breath you take. Every heartbeat. Every thought. Every immune response. All of it runs on a metabolic process that requires NAD+.

The molecule sits at the center of three jobs your cells cannot do without: producing ATP (the body's energy currency), repairing damaged DNA, and activating the sirtuin proteins that decide which genes turn on and which turn off as you age.

If your cells were a city, NAD+ is the electrical grid.

Now look at where you are on the curve:

1. By the time you are forty, you have roughly two-thirds of the NAD+ you had at twenty. 
2. By sixty, less than half. 
3. By seventy, the number falls below a third of young-adult baseline.

This is one of the most reproducible findings in modern aging science. It is not theory. It has been measured in skin biopsies, muscle biopsies, plasma, and liver tissue across multiple independent laboratories.

Whatever age you are reading this at, your NAD+ is closer to its low than its high. If you are in your forties or fifties, you are in the cliff phase. The grid is dimming on schedule.

Imai did not discover NAD+. He discovered something more important. He discovered that you can put it back.

What He Named, and What It Actually Does

The precursor Imai used has a name. Nicotinamide mononucleotide. NMN, for short.

It is one of the molecules your body uses to make NAD+ in the first place. Eat it, absorb it, and your cells convert it. The pathway is the body's own pathway. Imai did not build a new one. He found the missing input.

His lab published the foundational work in Cell Metabolism in 2011 (Yoshino et al.). He followed it with the long-term aging study in 2016 (Mills et al.), the one that ran old mice for twelve months and tracked age-related decline across organ systems.

These were the actual findings, recorded line by line in the publication:

• Mitochondrial function in skeletal muscle, restored.
• Insulin sensitivity, restored to the level of young controls.
• Energy metabolism, restored.
• Lipid metabolism, restored.
• Retinal photoreceptor function, restored.
• Bone density, improved.
• Physical activity, increased.
• Inflammation, reduced.
• Gene-expression patterns, shifted to match those of young animals.

Every system the lab looked at responded. Every one. The 2016 paper cleared peer review at Cell Metabolism, one of the most cited journals in cell biology on the planet.

Now compare what NMN does to what your American doctor is allowed to prescribe.

• Statins reduce the production of cholesterol in the liver. 
• Beta-blockers slow your heart rate to keep your blood pressure inside a window. 
• Antidepressants raise the level of one neurotransmitter to mask the symptoms of a deficit elsewhere.
• Diabetes medications push blood sugar down by forcing insulin secretion, blocking glucose absorption, or signaling satiety.

Each of those drugs does a useful job. None of them gives back something the body is running out of.

Imai showed the only intervention on record that does.

What Tokyo, Zurich, and Tel Aviv Did With It

This is the part of the story where four countries make four different choices about the same finding.

Three of them moved.

In Tokyo, longevity clinics began offering NAD+ restoration protocols in the early 2010s, when Imai's foundational papers were first hitting the journals. By the late 2010s, oral NMN was a standard recommendation in Japanese anti-aging medicine. NAD+ measurements were routine bloodwork at the clinics that catered to the senior Tokyo executive class.

In Zurich, the Swiss longevity-medicine industry, the most expensive in the world, folded NAD+ restoration into its standard concierge protocol. A week at Clinique La Prairie or Paracelsus runs into five figures and assumes NAD+ restoration as a baseline, not as an upsell.

In Tel Aviv, Israeli longevity programs built NMN and NAD+ infusion into geriatric and recovery medicine. Sheba Medical Center, consistently ranked among the top hospitals in the world, treats it as part of the standard kit, not as a fringe option.

In America, NAD+ is still flagged as "experimental" by most cardiologists, most primary-care physicians, and most insurance carriers. Not in the medical literature. In the clinical workflow.

Three of the most advanced medical economies on the planet built it in. The fourth one stayed on the sidelines.

The $400 Billion Reason They Keep Calling It Experimental

I want to name the enemy here. Specifically.

In 2024, the American Heart Association's own presidential advisory put U.S. cardiovascular healthcare costs at more than $400 billion a year, projected to triple to $1.34 trillion by 2050.

Stack diabetes, depression, and age-related disability on top of that column and the chronic-disease economy clears a trillion dollars annually. That is what these diseases cost the country. It is also, give or take, what they earn the largest medical-industrial sector in the country every year.

Here is what that means at the level of one person.

1. A single American adult on the mid-life chronic-disease cocktail (a statin plus a blood pressure drug plus an antidepressant plus a diabetes medication) is worth roughly $4,000 to $8,000 a year to that industry.

2. Every year. For the rest of their life. Run that across a 30-year diagnosis-to-death window and you are looking at $120,000 to $240,000 per patient in drug revenue alone, before a single procedure or hospitalization is added on top.

3. Multiply by the more than ninety million American adults on at least one of those four drug classes, per the most recent CDC prescription-utilization data.

Now look at the parallel market that already exists, for the people who do not need the system's permission.

In Manhattan, Miami, Aspen, and Beverly Hills, there is a quiet network of concierge longevity clinics that does not argue about whether NMN works. The men who use them are watching the same trial data as the rest of us; they just have the assistants to book the appointment.

• They pay $1,500 a session to sit in an IV chair.
• They do it twice a month.

The fact that this market exists, has existed quietly for the better part of a decade, and has grown every year of that decade, is the cleanest piece of evidence in this entire story that the science is settled in the places where the science gets to settle.

That is not a system uncertain about NMN.

That is a system uncertain how to keep its drug economy running if NMN becomes routine.

Heart disease, cardiovascular disease, diabetes, and the chronic conditions of age have been the leading causes of American death for fifty years. That is not a failure of the system. That is the system, operating exactly as designed. It is the most profitable patient population in American medicine, and the industry does not need a conspiracy to keep it that way. It just needs to keep paying for the research, the guidelines, and the medical-school curriculum that decide what your doctor is allowed to know.

NAD+ is older than the human species. NMN is a molecule the human body manufactures every single day. Neither of them can be patented at the molecular level. That is the original sin of NMN in American medicine. Everything that follows is downstream of that one fact.

Here is how a 2011 finding ends up labeled "experimental" in 2026, more than a decade after publication, in six steps:

1. A molecule emerges. 
   1. NMN is a molecule the human body already makes. It cannot be owned at the molecular level.
2. No ownership means no Phase III. 
   1. No pharmaceutical company will fund a $300 million pivotal trial for a compound their competitors can sell out of a bulk barrel the next morning. No Phase III, no FDA-recognized indication.
3. No indication means no guideline. 
   1. Search the American cardiology and primary-care guidelines today for NAD+ restoration as a metabolic target. It is not there.
4. No guideline means no reimbursement. 
   1. No CPT code for "measure NAD+ status." No billing code, no clinic workflow.
5. No reimbursement means no continuing medical education. 
   1. The conferences your doctor attends are funded by the companies whose drugs can be billed. The speakers are on consulting contracts with those same companies. NAD+ is, at best, a footnote on a slide nobody reads.
6. End of the line. 
   1. The Americans who can afford it pay $1,500 a session at concierge IV chairs. Or fly to longevity clinics in Cabo. Or buy research-chemical-grade NMN online from labs that will not tell them what is in the vial. Everyone else gets told to wait.

The system that decides what your doctor knows is funded by people who profit when you take a drug and lose when you replace what your cells are missing. The reason your father wasn't told about Imai is not that anyone buried him. It is that the industry never had a financial reason to dig him up.

Why You're Paying $1,500 at a Concierge IV, or Buying From a Lab That Won't Tell You What's in the Vial

Here is the last piece, and the one I have spent the most time on personally.

NMN is the answer. The molecule itself is what Imai showed. The science is not the problem. The molecule is not the problem.

The supply chain is the problem.

The American NMN market has two tiers, and most people don't know there is a third one being built.

Tier one is the concierge tier:

$1,500 a session for an IV chair. Assay-verified vials, clinical dosing, supply chain controlled by the clinic itself. The men who pay for this have been doing it for a decade. They are not waiting on FDA permission. They have already done the math.

Tier two is everyone else:

Independent lab tests have repeatedly found bottles of NMN from major Amazon and online sellers testing at less than half their label claim. Some batches contain no detectable NMN at all. Most labels do not disclose purity, stability data, or the analytical method used to verify the molecule. NMN is fragile, expensive to make at clinical grade, and easy to counterfeit. The honest manufacturers compete on a shelf next to the counterfeit ones, and the customer cannot tell them apart by looking at the bottle.

That is the gap. The molecule works. The molecule has been working in Tokyo and Zurich and Tel Aviv for ten years. What has been missing in this country is a version of NMN that delivers, at a price a normal household can sustain, the same molecule that the men in Manhattan have been paying $1,500 a session for.

• Clinical dose. The dose that actually shows up in the trials, not a sprinkle next to a label that name-drops them.
• Verified molecule. Third-party assay every batch, results disclosed.
• Stability data. The molecule that goes in the capsule is the molecule that comes out, after a year on the shelf.

A label that tells you the truth about what is in the bottle.

That is the version we have been building. More to come.

Your Father Wasn't Told. Your Sons Will Be. That Ends Here.

Your father wasn't told about Imai. Your sons won't be either, unless somebody builds the version of NMN the rest of us can actually use.

The science is not new. The decline is not new. The molecule is not new.

The only new part is that you are reading the name Imai in English, in 2026, from a supplement company instead of from your doctor.

That is the only part of this story that is actually our fault to fix. We intend to.

Stay close. The next email goes out this week.

If you haven't read the first piece on what NAD+ does and how it declines, start there: BANNED (FOR GOOD)! – The Real Reason NMN Is Being Taken Away.

Reply if this landed. I read every one.

Antonio
Founder, Black Forest Supplements